⏳ Final hours! Save up to 55% OFF InvestingProCLAIM SALE

UBS cuts Nutrien rating to neutral, lowers stock target on weaker market

EditorNatashya Angelica
Published 10-10-2024, 08:56 pm
NTR
-

On Thursday, UBS downgraded shares of Nutrien Ltd (NYSE:NTR), a major fertilizer company, from Buy to Neutral, significantly reducing the price target to $51 from $66. The firm cited a less optimistic outlook for the agricultural market as a key reason for the revised rating.

The downgrade comes amid expectations of a prolonged weaker agricultural market, which could impact Nutrien's medium-term performance. UBS's analysis suggests that the upside potential for Nutrien's stock is now less compelling, based on the latest earnings forecasts and free cash flow (FCF) projections.

UBS anticipates near-term risks to Nutrien's third-quarter earnings and sees limited potential for upward revisions to longer-term estimates. Although the firm's 2025 estimated EBITDA for Nutrien is approximately 4% above consensus, the expectation is for EBITDA to remain around $5.5 billion for the foreseeable future.

According to UBS, Nutrien's stock is projected to trade at a free cash flow yield of about 6%, which is considered close to fair value. The firm suggests that for the shares to become more attractive, there would need to be an increase in current fertilizer prices and a decrease in capital expenditures.

Nutrien, which is traded on the New York Stock Exchange under the ticker symbol NTR, is now positioned with a more cautious investment outlook by UBS, reflecting broader concerns in the agricultural sector.

In other recent news, Nutrien Ltd. has seen significant developments in both its financial performance and analyst ratings. The fertilizer company's earnings report highlighted an adjusted EBITDA of $3.3 billion for the first half of 2024, driven by increased crop input margins, strong demand for potash, and reduced operating costs. Despite challenges in the Brazilian market, Nutrien has raised its global potash demand forecast, signaling optimism for its long-term growth prospects.

Simultaneously, Goldman Sachs (NYSE:GS) downgraded Nutrien's stock from Buy to Neutral, citing concerns about potential increases in bad debt expense and loss reserves from the company's Retail segment. The firm also revised Nutrien's price target to $53, down from $69. BMO Capital also adjusted its outlook on Nutrien, reducing its price target from $80 to $75 due to a delay in progress within the Retail segment, but maintained its Outperform rating.

In addition to these changes, Nutrien announced a forthcoming CFO transition, with Mark Thompson set to assume the role later in the year. These recent developments reflect Nutrien's strategic moves in response to market dynamics and its commitment to maintaining its leadership in the fertilizer industry. As the company navigates the challenges presented by its Retail segment's lending operations, market participants continue to closely monitor Nutrien's financial stability.

InvestingPro Insights

In light of UBS's downgrade of Nutrien Ltd (NYSE:NTR), it's worth considering additional financial metrics and insights from InvestingPro. Despite the less optimistic outlook, Nutrien maintains a solid dividend yield of 4.41% and has raised its dividend for 6 consecutive years, as noted by an InvestingPro Tip. This could provide some stability for investors during uncertain market conditions.

The company's market capitalization stands at $24.24 billion, reflecting its significant presence in the fertilizer industry. An InvestingPro Tip highlights that Nutrien is a prominent player in the Chemicals sector, which aligns with its market position discussed in the article.

Interestingly, while UBS projects a free cash flow yield of about 6%, InvestingPro data shows a P/E ratio of 30.74, suggesting the stock may be trading at a premium relative to earnings. This high earnings multiple, also mentioned as an InvestingPro Tip, could be a factor in UBS's decision to downgrade the stock.

For investors seeking a more comprehensive analysis, InvestingPro offers 8 additional tips for Nutrien, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.